Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
  2. Our Web Sites |
  3. Global Business Websites |
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  

Contact Us

Sanofi-Aventis Ireland Limited

18 Riverwalk
Citywest Business Campus
Dublin 24

Tel : + 353 (0)1 403 5600

Content :

Valproate Educational Materials – Risk in Pregnancy

May 31, 2018

Following the PRAC decision relating to strengthening the warnings on the use of valproate in women and girls, as agreed with the HPRA educational materials are being made available to healthcare professionals and patients in order to inform about the risks associated with valproate in female children, women of childbearing potential and pregnant women.

The educational materials consist of:
Patient information cards

Patient information cards for girls and women of child-bearing age are available from your pharmacist. These cards complement the Valproate Patient Guide mentioned above.

Call for reporting

Please remember that any suspected adverse events should be reported to the Health Products Regulatory Authority (formerly the Irish Medicines Board), via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Company Contact

Adverse reactions can also be reported directly to Sanofi: email IEPharmacovigilance@sanofi.com or at telephone number (01) 4035600. Our medical information department can be contacted for further information at Uk-Medicalinformation@sanofi.com or at telephone number (01) 4035600.